New trial aims to help people with obesity lose weight without losing muscle

NCT ID NCT06854614

Ongoing Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining anti-obesity medications with a structured lifestyle program can help people with obesity lose weight and keep muscle. 150 participants will first take tirzepatide or semaglutide for 9 months, then switch to another oral medication for 12 months. The goal is to see which sequence works best for weight loss and muscle preservation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide, semaglutide, phentermine-topiramate, naltrexone-bupropion, orlistat
What this could lead to: If successful, this could point toward a more effective way to lose weight and maintain muscle using a sequence of anti-obesity medications.
What could go wrong: This is a relatively small, early-phase trial (150 people) and results may not apply to everyone. Side effects from the medications are possible, and the study is not designed to prove long-term safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.